Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

The global sarcoidosis therapeutics market is expected to be driven by research undertaking and funding to control the rising prevalence of sarcoidosis. For instance, the National Institutes of Health (NIH) granted US$ 8.3 Mn to the University of Pittsburgh to explore the relationship between gene activation process, sarcoidosis disease progression, and lung bacteria. Other major trends in global sarcoidosis therapeutics include strategic alliances. Pharma companies are working together or with research organizations to develop medications for the treatment of sarcoidosis. In March 2015, THERAMetrics Holding AG signed collaboration and licensing agreement with Centurion Pharma to develop and commercialize Aviptadil for sarcoidosis. In December 2018, aTyr Pharma announced collaboration with Foundation for Sarcoidosis Research (FSR) for assistance in clinical trial site initiation and patient enrollment for pulmonary sarcoidosis. Institutions and organizations are spreading awareness about sarcoidosis among people. In the U.K., the British Lung Foundation (BLF) is creating awareness about the early diagnosis and therapeutics of sarcoidosis.

https://www.transparencymarketresearch.com/sarcoidosis-therapeutics-market.html
LONDON--(BUSINESS WIRE)--Technavio analysts forecast the global sarcoidosis therapeutics market to have an incremental growth of $46 million during the forecast period [Global Sarcoidosis Therapeutics Market 2019-2023], according to their latest market research report. The growth momentum of the market is expected to accelerate in the year-over-year growth.

https://www.businesswire.com/news/home/20190104005221/en/Global-Sarcoidosis-Therapeutics-Market-2019-2023-Rising-Awareness-about-Sarcoidosis-to-Boost-Demand-Technavio